The startup develops a drug delivery technology that transforms conventional medications into extended-release formulations using biodegradable polymers as drug building blocks. This approach enables patients to achieve consistent linear drug release kinetics from a single treatment, enhancing therapeutic outcomes.
Funding
$230K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many drugs face limitations due to safety concerns, efficacy issues, patient compliance challenges, and high costs associated with frequent dosing. Traditional drug delivery methods often result in fluctuating drug concentrations, leading to inconsistent therapeutic effects and potential toxicity.
Solution
Viking Scientific is developing a novel drug delivery platform based on biodegradable hydrogels, created by polymerizing drug molecules directly into extended-release formulations. This approach enables consistent, linear drug release kinetics over days, weeks, or months from a single administration, eliminating the peaks and valleys associated with conventional dosing. The platform is designed to improve drug safety and efficacy, enhance patient compliance, and reduce overall treatment costs. Viking Scientific's technology is applicable to a wide range of drug classes, including small molecules, peptides, proteins, and antibodies, and can be administered through various routes, including IV infusion, local injection, surgical implant, and direct placement as a film.
Target Audience
The primary target audience includes pharmaceutical companies seeking to improve the delivery profiles of their existing or pipeline drug candidates, as well as healthcare providers aiming to enhance patient outcomes and reduce treatment burdens.
Features
- Hydrogels constructed from drug molecules themselves, eliminating separate drug-loading steps
- Customizable biodegradation rates to control drug release kinetics
- Ability to formulate drugs into particles, implants, or thin films for targeted delivery
- Compatibility with small molecules, large molecules, soluble drugs, and insoluble drugs
- Demonstrated sustained release of over 25 days in preclinical studies
- Potential for delivery via IV infusion, epidural injection, local injection, surgical implant, or direct placement
- Intellectual property protection with extensive patent claims covering various drug classes and therapeutic indications